10月25日，“十三五”国家科技重大专项成果——HIV-1 DNA载量检测试剂盒发布会在广州市黄埔区融媒体中心举办。本次会议由广州市创新领军团队携手广州海力特生物科技有限公司和暨南大学联合主办。海力特生物董事长、首席科学家朱托夫教授介绍，HIV ...

此次临床试验由 宾夕法尼亚大学 医学教授Ian Frank博士领导，于2018年至2019年间在美国六个地点招募了60名参与者。试验结果显示，PDPHV疫苗不仅安全，而且引发了强烈的免疫反应，特别是所有志愿者的CD4+ ...

红枫湾APP：HIV感染者中的病毒血症非进展者（VNPs）即使不进行抗逆转录病毒治疗（ART），病毒载量很高，CD4+T细胞计数也能长时间不下降。最近，IrsiCaixa艾滋病研究所在《医学（Med）》期刊上发表的一项多组学分析揭示了一现象的部分原因 ...

Early steps of infection by HIV-1 involve entry of the viral core into cells, reverse transcription to form the linear viral DNA, and integration of that DNA into a chromosome of the host.

通过多组学分析，一项新的研究揭示了一些称为病毒血症非进展者（viremic non-progressor, VNP）的HIV感染者在不接受抗逆转录病毒疗法（ART）的情况下避免疾病进展的遗传和 免疫 ...

We therefore developed a strategy to assemble the full–length HIV–1 clones by using PCR–mediated recombination (Fig. 1). The four DNA fragments (A, B, C and D) encompassing the full–length ...

Immuno Cure’s ICVAX aims to induce broadly reactive polyfunctional viral-specific T cells to achieve sustained HIV-1 ...

This valuable study uses robust time-dependent microscopy assays to show that during HIV-1 infection, the viral accessory protein Vif causes cell cycle arrest during metaphase and not G2/M as ...

Gammora is a HIV-1 integrase-derived peptide that works to target the disease by stimulating the insertion of the virus’s ...

HONG KONG SAR - Media OutReach Newswire – 12 November 2024 - Immuno Cure BioTech (" Immuno Cure "), a clinical-stage ...

Before initiating ART, VNPs showed significantly lower total and intact HIV-1 DNA levels in their peripheral blood ...

Of these, only 1 percent will work their way into the nuclei ... You have just produced a naked-DNA HIV vaccine. Trials for a genetic vaccine that may protect against AIDS began in 1995.